Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more
Market Cap & Net Worth: Microba Life Sciences Ltd (MAP)
Microba Life Sciences Ltd (AU:MAP) has a market capitalization of $30.16 Million (AU$48.72 Million) as of March 18, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28338 globally and #730 in its home market, demonstrating a -1.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Microba Life Sciences Ltd's stock price AU$0.08 by its total outstanding shares 608963034 (608.96 Million).
Microba Life Sciences Ltd Market Cap History: 2022 to 2026
Microba Life Sciences Ltd's market capitalization history from 2022 to 2026. Data shows change from $125.37 Million to $30.16 Million (-31.17% CAGR).
Microba Life Sciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Microba Life Sciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.69x
Microba Life Sciences Ltd's market cap is 4.69 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $125.37 Million | $5.42 Million | -$12.68 Million | 23.13x | N/A |
| 2023 | $67.87 Million | $12.09 Million | -$19.94 Million | 5.61x | N/A |
| 2024 | $73.53 Million | $15.67 Million | -$14.94 Million | 4.69x | N/A |
Competitor Companies of MAP by Market Capitalization
Companies near Microba Life Sciences Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Microba Life Sciences Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Microba Life Sciences Ltd Historical Marketcap From 2022 to 2026
Between 2022 and today, Microba Life Sciences Ltd's market cap moved from $125.37 Million to $ 30.16 Million, with a yearly change of -31.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$30.16 Million | +5.26% |
| 2025 | AU$28.66 Million | -61.03% |
| 2024 | AU$73.53 Million | +8.33% |
| 2023 | AU$67.87 Million | -45.86% |
| 2022 | AU$125.37 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Microba Life Sciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.16 Million USD |
| MoneyControl | $30.16 Million USD |
| MarketWatch | $30.16 Million USD |
| marketcap.company | $30.16 Million USD |
| Reuters | $30.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.